Skip to content

Myriad Genetics MYGN Free cash flow yield

Free cash flow yield at other companies

Labcorp Holdings logo
Labcorp HoldingsLH
6.3%+0.4pp
Quest Diagnostics logo
Quest DiagnosticsDGX
6.2%+0.5pp
NeoGenomics logo
NeoGenomicsNEO
-2.7%
Veracyte logo
VeracyteVCYT
6.1%+2.7pp
Guardant Health logo
Guardant HealthGH
-2%-0.8pp
Natera, Inc. logo
Natera, Inc.NTRA
0.4%-0.1pp

Other financials

Income statement

See full
Revenue$200.4M+2.3%
Gross profit$137.6M+2.5%
Operating income-$30.7M-5.9%
Net income-$34.1M-34,000%
EPS (diluted)-$0.36

Balance sheet

See full
Cash & equivalents$126.0M+24.8%
Total debt$211.5M+34.2%
Total equity$337.4M-52.1%
Total assets$673.7M-33.0%

Cash flow

See full
Operating cash flow-$15.7M+3.7%
CapEx$18.8M+181%
Free cash flow-$19.7M+65.1%

Valuation

See full
Market cap$512.85M+13.1%
Enterprise value$598.35M+17.3%
P/S0.6×+0.1×

Profitability

See full
Gross margin70%0.0pp
Operating margin-46.9%-88.3pp
Net margin-48.2%-72.9pp
FCF margin-17%

Returns & leverage

See full
Return on equity-76.7%-98.4pp
Debt / equity0.6×+0.4×
Current ratio2.4×+0.5×

Where this comes from

Calculated from Myriad Genetics’s reported figures.

Based on trailing twelve months.

The official record: Myriad Genetics’s 10-Q, filed August 7, 2024, on SEC EDGAR. View the filing →

Ask your AI about Myriad Genetics's free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Myriad Genetics's free cash flow yield?
Myriad Genetics (MYGN) reported free cash flow yield of -6.3% in Q2 2023.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.